Brii Biosciences hits near 11-week high as China approves its COVID-19 treatment

Brii Biosciences

09/12/2021 05:39

`    ** Shares of infectious diseases-focused biotechnology
group Brii Biosciences Ltd  2137.HK  jump as much as 13.7% to
HK$48.65, their highest since Sept. 24
    ** Stock on track for the third straight session of gains
    ** Beijing-based company says China's National Medical
Products Administration has granted approval for the firm's
monoclonal neutralizing antibody therapy - the
amubarvimab/romlusevimab combination, for treatment in adults
and pediatric patients with mild and normal type of COVID-19
 urn:newsml:reuters.com:*:nFWN2ST16L
    ** Says the approval marks the first locally-discovered and
approved SARS-CoV-2 target-specific treatment in China, through
a randomized, double-blind and placebo-controlled trial
    ** Co says it is seeking U.S. FDA Emergency Use
Authorization for the amubarvimab/romlusevimab combination
    ** The Hang Seng Commerce & Industry Index  .HSNC  rises
1.4%, and the healthcare index  .HSCIH  jumps 3.2%
    ** The Hang Seng Composite Index  .HSCI  rises 1.3% and the
benchmark Hang Seng Index  .HSI  climbs 1%


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))